TABLE 2.

Clinical characteristics of the study population

Characteristics	Control (n = 16)	AUD active (n = 62)	AUD abstinent (n = 56)	p value
CAP, n = 92	n/a	285.1 ± 57.9	244.2 ± 59.2	0.003
LSM (kPa), n = 92	n/a	7.67 ± 9.71	9.75 ± 12.20	0.418
CK18‐M65 (U/L), n = 114	183.5 ± 64.5	469.5 ± 387.3	295.1 ± 255.2	*0.006

Values presented are mean ± SD. The number of subjects for which data were available is indicated in the first column.

Abbreviations: AUD, alcohol use disorder; CAP, controlled attenuation parameter; CK18‐M65, caspase‐cleaved and intact cytokeratin 18; LSM, liver stiffness measurement; n/a, not applicable.

^*Post hoc p values for CK18‐M65: control versus AUD active, p < 0.001; control versus AUD abstinent, p = 0.014; AUD active versus AUD abstinent, p = 0.006.